Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 18Nivolumab 6Radiotherapy 5Paclitaxel 5Trastuzumab 4Specimen Handling 4Ipilimumab 4tisotumab vedotin 3temsirolimus 3olaparib 3lenvatinib 3X-Rays 3Taxes 3Surveys and Questionnaires 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Biopsy 3spartalizumab 2sargramostim 2rucaparib 2palbociclib 2fludarabine 2epacadostat 2enzalutamide 2durvalumab 2cabozantinib 2atezolizumab 2aflibercept 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × zanidatamab × Genitourinary × Clear all
NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Phase 2 Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡